IgE Protein
-
- Target Alle IgE Proteine anzeigen
- IgE
- Protein-Typ
- Recombinant
-
Spezies
- Human
-
Quelle
- Human
- Applikation
- Western Blotting (WB), Isotype Control (IsoC), ELISA, Functional Studies (Func), Flow Cytometry (FACS)
- Spezifität
- Binds with Fc effector domain to human and non human primate IgE receptors, no cross-reactivity with rodent or canine IgE receptors, specific antigen unknown
- Produktmerkmale
-
IGHE, chromosome 14q32.33
Source of protein: Human B cell hybridoma from healthy donors (CD40 cell culture system) - Aufreinigung
- Affinity - purified from cell culture supernatant by Immunoaffinity Chromatography on CH-Sepharose 4B
- Reinheit
- > 95 %, tested by analytical Gel Permeation Chromatography
- Sterilität
- Sterile filtered
- Top Product
- Discover our top product IgE Protein
-
-
- Applikationshinweise
- For functional cellular assays (mast cell / basophil activation), in particular when used at dilutions < 1:100 Quality assurance: Reactivity > 99 %, compared to calibrator (Internal Standard mAb BSW17), tested by ELISA binding to immobilized human Standard IgE (SUS-11)
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Konzentration
- 1 mg/mL
- Buffer
- PBS, pH=7.2, sterile filtered, contains no NaN3
- Konservierungsmittel
- Azide free
- Lagerung
- 4 °C
-
- Target
- IgE
- Abstract
- IgE Produkte
- Synonyme
- IGH2 Protein, IgE Protein, Gm900 Protein, immunoglobulin heavy chain (epsilon polypeptide) Protein, immunoglobulin heavy constant epsilon Protein, Immunoglobulin heavy constant epsilon Protein, Ighe Protein, IGHE Protein
- Hintergrund
- Recombinant human IgE to be used as reference for IgE concentration measurements in biological samples (ELISA, FACS). IgE (SUS-11) recognizes the human high affinity IgE receptor (FceRIa), the human low affinity IgE receptor (CD23) and does not interact with the corresponding IgE receptors of other species. It can be used as functional reagent in mast cell / basophil cellular assays, e.g. for controlled sensitization of such cells and subsequent cross-linking with either anti-human IgE mAbs mAb LE27 or a specific recombinant cross-linking agent.
-